PortfoliosLab logo
PureTech Health plc (PRTC)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US7462371060

CUSIP

746237106

IPO Date

Nov 16, 2020

Highlights

Market Cap

$435.09M

EPS (TTM)

$2.10

PE Ratio

8.48

Total Revenue (TTM)

$288.00K

Gross Profit (TTM)

-$38.64M

EBITDA (TTM)

-$64.58M

Year Range

$13.30 - $32.98

Target Price

$53.25

Short %

0.06%

Short Ratio

1.00

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


PureTech Health plc

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

PureTech Health plc (PRTC) returned -0.54% year-to-date (YTD) and -37.23% over the past 12 months.


PRTC

YTD

-0.54%

1M

4.91%

6M

-21.50%

1Y

-37.23%

3Y*

-7.77%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

0.51%

1M

6.15%

6M

-2.00%

1Y

12.92%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of PRTC, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20253.47%-6.81%11.12%-12.74%6.37%-0.54%
2024-10.75%0.20%13.10%-2.14%18.25%-24.20%-10.92%3.28%-10.37%-1.29%9.14%-16.88%-34.49%
2023-0.31%-8.84%0.00%-11.18%6.80%8.36%-4.03%-16.43%-3.77%-21.74%10.83%41.25%-11.66%
20220.03%-19.75%-14.95%-18.45%9.47%-6.83%17.28%17.69%-6.90%3.78%24.91%-8.86%-13.78%
20210.00%1.36%8.03%-3.94%-1.65%-12.28%-2.67%4.84%-4.02%1.42%-10.48%-15.08%-31.48%
20203.64%35.34%40.26%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of PRTC is 19, meaning it’s performing worse than 81% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of PRTC is 1919
Overall Rank
The Sharpe Ratio Rank of PRTC is 1515
Sharpe Ratio Rank
The Sortino Ratio Rank of PRTC is 1616
Sortino Ratio Rank
The Omega Ratio Rank of PRTC is 1818
Omega Ratio Rank
The Calmar Ratio Rank of PRTC is 2020
Calmar Ratio Rank
The Martin Ratio Rank of PRTC is 2727
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for PureTech Health plc (PRTC) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

PureTech Health plc Sharpe ratios as of May 30, 2025 (values are recalculated daily):

  • 1-Year: -0.65
  • All Time: -0.24

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of PureTech Health plc compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


PureTech Health plc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the PureTech Health plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the PureTech Health plc was 78.91%, occurring on Apr 10, 2025. The portfolio has not yet recovered.

The current PureTech Health plc drawdown is 71.31%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-78.91%Mar 31, 20211013Apr 10, 2025
-18.35%Jan 8, 202110Jan 22, 202145Mar 29, 202155
-4.66%Nov 18, 20206Nov 25, 20204Dec 2, 202010
-0.97%Jan 5, 20211Jan 5, 20212Jan 7, 20213
-0.88%Dec 9, 20201Dec 9, 20201Dec 10, 20202
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of PureTech Health plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of PureTech Health plc, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 100.0% positive surprise.


-4.00-3.00-2.00-1.000.001.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober20240
-1.98
Actual
Estimate

Valuation

The Valuation section provides an overview of how PureTech Health plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for PRTC, comparing it with other companies in the Biotechnology industry. Currently, PRTC has a P/E ratio of 8.5. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for PRTC relative to other companies in the Biotechnology industry. Currently, PRTC has a P/S ratio of 90.1. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for PRTC in comparison with other companies in the Biotechnology industry. Currently, PRTC has a P/B value of 1.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items